H L Kindler

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
    H L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA
    Ann Oncol 23:2834-42. 2012
  2. pmc Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
    Hedy L Kindler
    University of Chicago ComprehensiveCancer Center, Chicago, IL, USA
    J Clin Oncol 30:2509-15. 2012
  3. ncbi request reprint 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Invest New Drugs 22:323-7. 2004
  4. pmc Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    Hedy Lee Kindler
    University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    J Clin Oncol 28:3617-22. 2010
  5. doi request reprint Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637 1463, USA
    Am J Clin Oncol 31:553-6. 2008
  6. ncbi request reprint Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma
    Hedy L Kindler
    Department of Hematology Oncology, Medical Center, University of Chicago, 5841 South Maryland Avenue, MC 2115, IL 60637 1470, USA
    Lung Cancer 45:S125-7. 2004
  7. pmc Systemic treatments for mesothelioma: standard and novel
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Curr Treat Options Oncol 9:171-9. 2008
  8. doi request reprint A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer
    Hedy Lee Kindler
    University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL, 60637 1460, USA
    Invest New Drugs 27:75-81. 2009
  9. ncbi request reprint Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B
    Hedy L Kindler
    University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Lung Cancer 48:423-8. 2005
  10. ncbi request reprint Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer
    Hedy Lee Kindler
    University of Chicago Medical Center, Illinois 60637 1470, USA
    Am J Clin Oncol 28:340-4. 2005

Detail Information

Publications54

  1. doi request reprint A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
    H L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA
    Ann Oncol 23:2834-42. 2012
    ....
  2. pmc Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
    Hedy L Kindler
    University of Chicago ComprehensiveCancer Center, Chicago, IL, USA
    J Clin Oncol 30:2509-15. 2012
    ..We added the anti-VEGF antibody bevacizumab to gemcitabine/cisplatin in a multicenter, double-blind, placebo-controlled randomized phase II trial in patients with previously untreated, unresectable MM...
  3. ncbi request reprint 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Invest New Drugs 22:323-7. 2004
    ..Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer...
  4. pmc Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    Hedy Lee Kindler
    University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    J Clin Oncol 28:3617-22. 2010
    ..These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients...
  5. doi request reprint Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637 1463, USA
    Am J Clin Oncol 31:553-6. 2008
    ..We conducted a multicenter phase II trial in patients with advanced pancreatic cancer who experienced disease progression on or after a gemcitabine-containing regimen...
  6. ncbi request reprint Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma
    Hedy L Kindler
    Department of Hematology Oncology, Medical Center, University of Chicago, 5841 South Maryland Avenue, MC 2115, IL 60637 1470, USA
    Lung Cancer 45:S125-7. 2004
    ..Two clinical trials are planned to evaluate the two PDGF inhibitors Gleevec (Imatinib mesylate, STI-571, Novartis Pharmaceuticals) and PTK787 (Novartis Pharmaceuticals)...
  7. pmc Systemic treatments for mesothelioma: standard and novel
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Curr Treat Options Oncol 9:171-9. 2008
    ..Given the progress made in recent years, there is reason to believe that more effective treatments will continue to be developed...
  8. doi request reprint A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer
    Hedy Lee Kindler
    University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL, 60637 1460, USA
    Invest New Drugs 27:75-81. 2009
    ..This phase II study was designed to evaluate the efficacy and safety of L-alanosine in patients with MTAP-deficient solid tumors...
  9. ncbi request reprint Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B
    Hedy L Kindler
    University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Lung Cancer 48:423-8. 2005
    ..The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733)...
  10. ncbi request reprint Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer
    Hedy Lee Kindler
    University of Chicago Medical Center, Illinois 60637 1470, USA
    Am J Clin Oncol 28:340-4. 2005
    ..The authors conclude that the combination of gefitinib plus oxaliplatin is inactive in advanced colorectal cancer...
  11. ncbi request reprint Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Invest New Drugs 23:489-93. 2005
    ..We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma...
  12. ncbi request reprint Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, IL 60637, USA
    J Clin Oncol 23:8033-40. 2005
    ..The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab...
  13. ncbi request reprint Pancreatic cancer: an update
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago, MC 2115, Chicago, IL 60637 1470, USA
    Curr Oncol Rep 9:170-6. 2007
    ..Several key negative studies have also been reported recently. This review discusses recent trials that have changed the standard of care for patients with advanced pancreatic cancer...
  14. doi request reprint Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Invest New Drugs 30:382-6. 2012
    ..Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease...
  15. ncbi request reprint Front-line therapy of advanced pancreatic cancer
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Semin Oncol 32:S33-6. 2005
    ..Agents that target vascular endothelial growth factor and the epidermal growth factor receptor are currently being evaluated in phase III trials...
  16. ncbi request reprint Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
    H L Kindler
    University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Lung Cancer 31:311-7. 2001
    ..The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530)...
  17. ncbi request reprint Metastatic colorectal cancer
    H L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Curr Treat Options Oncol 2:459-71. 2001
    ..The emergence of these new drugs and new interventional modalities has allowed physicians who treat colorectal cancer to move beyond 5-FU...
  18. ncbi request reprint The pemetrexed/gemcitabine combination in pancreatic cancer
    Hedy Lee Kindler
    Director of Gastrointestinal Oncology, Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 95:928-32. 2002
    ..The promising activity observed in this study has led to an ongoing international, randomized, Phase III trial in 520 patients comparing the pemetrexed/gemcitabine combination with gemcitabine alone...
  19. doi request reprint Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
    Hedy L Kindler
    University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA
    Lancet Oncol 12:256-62. 2011
    ..On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial...
  20. ncbi request reprint A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer
    C Eng
    Department of Medicine, Section of Hematology Oncology, University of Chicago, IL 60612, USA
    Ann Oncol 15:928-32. 2004
    ..We conducted a phase II study of single-agent BMS-247550 in advanced colorectal cancer patients who had disease progression following treatment with irinotecan-5-fluorouracil-leucovorin (IFL)...
  21. ncbi request reprint Oral fluoropyrimidine treatment of colorectal cancer
    C Eng
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, USA
    Clin Colorectal Cancer 1:95-103. 2001
    ..The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer...
  22. ncbi request reprint A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
    S D Undevia
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Ann Oncol 15:1705-11. 2004
    ..This study was conducted to determine the toxicity profile, maximum tolerated dose (MTD) and pharmacokinetics of the putative histone deacetylase inhibitor CI-994 in combination with capecitabine...
  23. pmc Disease volumes as a marker for patient response in malignant pleural mesothelioma
    Z E Labby
    Department of Radiology, The University of Chicago, Chicago, IL 60637, USA
    Ann Oncol 24:999-1005. 2013
    ....
  24. ncbi request reprint Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction
    A B Sandler
    Department of Medicine, Indiana University, Indianapolis, USA
    Ann Oncol 11:1161-4. 2000
    ....
  25. ncbi request reprint A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma
    Cathy Eng
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Am J Clin Oncol 27:565-9. 2004
    ..Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma...
  26. ncbi request reprint Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase
    R L Schilsky
    Biological Sciences Division, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Expert Opin Investig Drugs 9:1635-49. 2000
    ..Eniluracil is a promising drug, which permits reliable and safe administration of oral 5-FU and has the potential to overcome 5-FU resistance mediated by overexpression of DPD...
  27. ncbi request reprint Phase II study of flavopiridol in patients with advanced colorectal cancer
    M Aklilu
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Ann Oncol 14:1270-3. 2003
    ..We evaluated flavopiridol in a phase II trial in patients with previously untreated advanced colorectal cancer (ACRC)...
  28. pmc Computerized segmentation and measurement of malignant pleural mesothelioma
    William F Sensakovic
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
    Med Phys 38:238-44. 2011
    ..This manuscript presents a computerized method for the three-dimensional segmentation and volumetric analysis of MPM...
  29. ncbi request reprint Current state and future directions of pleural mesothelioma imaging
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637, USA
    Lung Cancer 59:411-20. 2008
    ..From diagnosis to response, PET/CT to molecular bioprobes, volumetric analysis to computerized tumor assessment, imaging promises to provide valuable insight for patients with mesothelioma and the physicians who treat them...
  30. ncbi request reprint Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy
    Loren K Mell
    Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 70:1431-7. 2008
    ....
  31. pmc A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours
    Samir D Undevia
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Eur J Cancer 44:1684-92. 2008
    ..Preclinical studies suggested that efficacy was independent of schedule but that toxicity was decreased by dividing the dose...
  32. ncbi request reprint The cancer and leukemia group B respiratory committee
    Everett E Vokes
    The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 12:3581s-8s. 2006
    ..We look forward to making additional critical contributions during future decades of Cancer and Leukemia Group B Respiratory Committee research...
  33. ncbi request reprint A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903
    Mitchell C Posner
    University of Chicago, 5841 S Maryland Avenue MC5031, Chicago 60637, IL, USA
    Ann Surg Oncol 15:158-64. 2008
    ....
  34. ncbi request reprint Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer
    Sridhar Mani
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:1042-8. 2002
    ..Our study warrants further exploration of efficacy in a Phase II and/or Phase III clinical trial setting...
  35. ncbi request reprint Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
    Med Phys 31:1105-15. 2004
    ..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers...
  36. ncbi request reprint Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer
    Richard L Schilsky
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 20:582-7. 2002
    ..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination...
  37. ncbi request reprint Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Acad Radiol 12:1301-9. 2005
    ..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans...
  38. ncbi request reprint Variability in mesothelioma tumor response classification
    Samuel G Armato
    Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
    AJR Am J Roentgenol 186:1000-6. 2006
    ..In addition, the performance of a semiautomated measurement method was evaluated...
  39. ncbi request reprint Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer
    Apurva A Desai
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 56:421-6. 2005
    ..Hence, we conducted this phase II trial in patients with colorectal cancer (CRC) to further evaluate the toxicity and activity of irinotecan modulated with cyclosporine...
  40. pmc Personalized colon cancer care in 2010
    Daniel V T Catenacci
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:284-308. 2011
    ..We then review strategies that will potentially improve our ability to individualize therapy in the future...
  41. pmc Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication
    William F Sensakovic
    Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Acad Radiol 18:294-8. 2011
    ....
  42. ncbi request reprint Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study
    Charles M Rudin
    The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 10:7244-51. 2004
    ..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)...
  43. ncbi request reprint Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies
    Christopher W Ryan
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Cancer Res 10:4406-11. 2004
    ..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies...
  44. pmc Protein kinase C beta in malignant pleural mesothelioma
    Leonardo Faoro
    Section of Hematology Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Anticancer Drugs 19:841-8. 2008
    ..Enzastaurin has preclinical activity against MPM, and exhibited synergism with cisplatin. PKCbeta inhibition in MPM might be able to reduce the invasiveness of MPM by affecting cytoskeletal function...
  45. ncbi request reprint A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors
    Paul R Helft
    University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 10:4363-8. 2004
    ..v. infusion without interruption...
  46. ncbi request reprint Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
    Ramasamy Jagadeeswaran
    Section of Hematology Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Cancer Res 66:352-61. 2006
    ..Ultimately, c-Met would be an important target for therapy against MPM...
  47. ncbi request reprint The role of gemcitabine in the treatment of malignant mesothelioma
    Hedy Lee Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 29:70-6. 2002
    ....
  48. ncbi request reprint New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents
    Anna K Nowak
    University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia
    Semin Oncol 29:82-96. 2002
    ..The development of more active cytotoxic combinations in this disease should facilitate further studies of chemoimmunotherapy. It seems likely that no single treatment modality will be effective by itself...
  49. ncbi request reprint Pemetrexed in pancreatic cancer
    Hedy Lee Kindler
    Section of Hematology Oncology, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 29:49-53. 2002
    ..A 520-patient international randomized phase III trial that compares the pemetrexed/gemcitabine combination with single-agent gemcitabine is currently accruing patients...
  50. ncbi request reprint The emerging role of pemetrexed for the treatment of malignant mesothelioma
    Hedy Lee Kindler
    University of Chicago, Chicago, Illinois 60637 1463, USA
    Oncology (Williston Park) 18:49-53. 2004
    ..Additional trials are evaluating pemetrexed in the neoadjuvant setting and in combination with other cytotoxic and targeted agents...
  51. ncbi request reprint A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy
    Kai Bickenbach
    Department of Surgery, University of Chicago Pritzker School of Medicine, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    J Gastrointest Surg 11:758-66. 2007
    ..We highlight this review with an interesting case report that illustrates unique phenotypic tumoral changes associated with imatinib mesylate resistance...
  52. ncbi request reprint In focus: advanced pancreatic cancer
    Hedy Lee Kindler
    University of Chicago, Chicago, IL 60637, USA
    Clin Adv Hematol Oncol 3:420-2. 2005
  53. ncbi request reprint Chemotherapy for advanced pancreatic cancer: past, present, and future
    Gregory Friberg
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Curr Oncol Rep 7:186-95. 2005
    ....
  54. ncbi request reprint Antiangiogenic therapies for mesothelioma
    Jonathan E Dowell
    University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Hematol Oncol Clin North Am 19:1137-45, viii. 2005
    ..Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions...